本文選題：糖尿病 + 型�。� 參考：《中國(guó)新藥與臨床雜志》2017年11期

【摘要】：目的探討利拉魯肽和門冬胰島素30治療2型糖尿病輕度認(rèn)知損傷(MCI)的有效性、安全性及其對(duì)認(rèn)知功能的影響和差異。方法 2型糖尿病MCI患者80例,隨機(jī)分為兩組,每組40例,胰島素組維持原門冬胰島素30治療,利拉魯肽組改為利拉魯肽治療,療程均為48周。治療前和治療12、24、36、48周末測(cè)定患者血糖、血脂和血壓水平,計(jì)算體重指數(shù)(BMI),進(jìn)行蒙特利爾認(rèn)知評(píng)估(MoCA)量表評(píng)分,并記錄血糖達(dá)標(biāo)[糖化血紅蛋白(HbA_(1c))≤7%]、低血糖及癡呆發(fā)生情況。結(jié)果胰島素組和利拉魯肽組各完成39例和38例。治療24、36周末,利拉魯肽組三酰甘油水平顯著低于胰島素組(P0.01),48周末HbA_(1c)水平低于胰島素組(P0.05),Mo CA量表評(píng)分高于胰島素組(P0.05)。胰島素組和利拉魯肽組血糖達(dá)標(biāo)率分別為77%(30/39)和84%(32/38),癡呆發(fā)生率分別為5%(2/39)和0,差異均無(wú)顯著意義(P0.05);低血糖發(fā)生率分別為64%(25/39)和24%(9/38),利拉魯肽組低于胰島素組(P0.01)。結(jié)論與門冬胰島素30相比,利拉魯肽治療2型糖尿病MCI患者,可更好地控制HbA_(1c),低血糖發(fā)生率更低,并可改善患者認(rèn)知功能。
[Abstract]:Objective to investigate the efficacy, safety and effects on cognitive function of patients with mild cognitive impairment of type 2 diabetes mellitus (MCI) treated with Lilaru peptide and aspartate 30. Methods 80 MCI patients with type 2 diabetes were randomly divided into two groups, 40 cases in each group. The blood glucose, blood lipid and blood pressure were measured before treatment and at the end of 12 weeks after treatment. The body mass index (BMI) was calculated, and the Montreal Cognitive Assessment scale (MOCA) was used to evaluate the blood glucose standard (HbA1cU) 鈮，

本文編號(hào)：2003301